Here are the Form 4 insider transactions from Akero Therapeutics, Inc. (AKRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKRO filings page.
Akero Therapeutics’ Chief Scientific Officer reported the completion of a merger in which Novo Nordisk A/S acquired Akero through a cash-and-contingent value right structure. At the effective time on December 9, 2025, each share of Akero common stock held by the officer was cancelled and converted into the right to receive $54.00 in cash plus one contractual contingent value right that may pay $6.00 in cash if a specified milestone is achieved.
The report also shows that the officer’s restricted stock units became fully vested at closing and were converted into the same merger consideration for each underlying share. All compensatory stock options to purchase Akero common stock, whether vested or unvested, were cancelled and converted into a cash payment based on the excess of the $54.00 cash price over each option’s exercise price, plus one contingent value right for each underlying share, in line with the merger agreement.
Akero Therapeutics, Inc. Chief Operating Officer Form 4 activity reports stock option exercises and a charitable gift of common stock. On 11/24/2025, the reporting person exercised three stock option grants, acquiring 4,284 shares at an exercise price of $21.09, 3,527 shares at $28.35, and 4,739 shares at $21.10. After these exercises, direct holdings increased, and following the reported transactions the person directly owned 200,189 shares of Akero common stock.
On 11/26/2025, the individual reported a transaction coded as a gift, transferring 9,259 shares of common stock at a reported price of $0 to a donor advised fund. In addition to direct ownership, the filing shows indirect ownership of 20,000 Akero shares in each of three irrevocable trusts for the benefit of the reporting person’s children, for a total of 60,000 indirectly held shares. The reporting person disclaims beneficial ownership of the trust-held securities, and notes that the stock options exercised are vested and currently exercisable.
Akero Therapeutics, Inc. insider ownership changed due to a charitable gift. The company’s President, CEO, and director reported donating 74,538 shares of Akero Therapeutics common stock as a gift to a donor advised fund on 11/20/2025. The transaction was reported with a price of $0, consistent with a non-cash charitable transfer rather than a market sale.
Following this gift, the reporting person directly beneficially owns 436,837 shares of Akero Therapeutics common stock. This Form 4 filing documents the change in beneficial ownership for regulatory disclosure purposes and does not describe any open-market purchase or sale.
Akero Therapeutics (AKRO) reported an insider stock gift by its Chief Scientific Officer. On 11/17/2025, the executive donated 37,100 shares of Akero common stock as a gift to a donor advised fund, with the transaction reported at a price of $0 per share, reflecting the non-sale nature of the transfer. After this charitable transfer, the reporting person beneficially owns 129,471 shares of Akero common stock in direct ownership form. This filing documents a change in the executive’s personal holdings without involving an open-market sale or purchase of shares.
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a Director. On 11/12/2025, the insider made a bona fide charitable gift of 14,739 shares of common stock, reported as code G at a stated price of $0. Following the transaction, the insider’s beneficial ownership stands at 511,375 shares, held directly.
The explanation notes the recipient is a 501(c)(3) organization and the reporting person has no pecuniary interest in that entity.